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CASE REPORT
Scaly Ear Rash as the Herald of a Young Girl with 
Juvenile Systemic Lupus Erythematosus 
Ching-Fu Huang, M.D., Wei-Ming Wang, M.D., Ph.D., Chien-Ping Chiang, M.D., Ph.D.
Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Juvenile systemic lupus erythematosus (JSLE) is an autoim-
mune-mediated multiorgan disease. The cutaneous manifes-
tation is one of the most common initial presentations in JSLE. 
A typical lesion is a facial malar rash, but a patient may 
sometimes present with nonclassical lesions. Herein, we 
report two cases of JSLE with similar persistent scaly ear 
rashes as the heralding cutaneous symptom preceding 
systemic symptoms. Identifying this atypical and underes-
timated cutaneous rash in juvenile patients might help the 
clinician make the correct diagnosis and provide earlier 
intervention, which may help prevent disease progression.
(Ann Dermatol 23(S3) S333∼S337, 2011)
-Keywords-
Juvenile systemic lupus erythematosus, Ear, Rash
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune 
condition involving inflammation of multiple organs. In 
contrast to adult SLE, the prevalence rate of juvenile SLE is 
very low, less than 1/100,000
1, although black children 
have a higher incidence
2. Juvenile SLE (JSLE) is clinically 
similar to adult SLE, but there are some differences bet-
ween JSLE and adult SLE. We, herein, report two rare 
cases of JSLE involving a similar scaly ear rash followed by 
a facial rash and constitutional symptoms.
CASE REPORT
The first patient was a 12-year-old girl who presented with 
an asymptomatic skin rash on her left ear that had per-
sisted for more than 4 weeks. About 2 weeks before pre-
senting to our clinic, she experienced constitutional symp-
toms such as dyspnea, sore throat, and a low-grade fever 
of 38
oC. A skin rash was noted on her face, chest, upper 
neck, and dorsal aspect of the forearms. The patient was 
initially diagnosed with an acute viral infection at a local 
clinic. However, the symptoms worsened and more skin 
lesions appeared on her body. Because of the persistent 
symptoms, the patient was transferred to our center for 
evaluation. A review of the patient’s medical history 
showed no significant findings, except that her mother 
had a history of idiopathic hemolytic anemia.
On dermatological examination, a well-demarcated scaly 
erythematous plaque was found on the patient’s left ear 
(Fig. 1A). Numerous erythematous papules with scales 
were noted on the anterior neck, chest, and both fo-
rearms. The characteristic confluent symmetric erythema 
and edema were centered over the malar eminence and 
bridge of the nose, but the nasolabial folds were spared 
(Fig. 1B). Other extracutaneous lesions included an oral 
ulcer on the hard palate (Fig. 1C) and erythema with 
telangiectasia around the proximal nail fold.
Initial laboratory testing showed the following values: 
hemoglobin, 8.1 g/dl (reference range, 12∼16 g/dl); white 
blood cell (WBC) count, 3,400/mm
3 (4,500∼1,0000/ 
mm
3); aspartate transaminase, 81 U/L (＜32 U/L), alanine 
transaminase, 52 U/L (＜31 U/L); total bilirubin, 1.5 mg/dl 
(＜1.2 mg/dl); indirect bilirubin, 0.5 mg/dl (＜0.2 mg/dl); 
and erythrocyte sedimentation rate, 99 mm/h (＜20 CF Huang, et al
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Fig. 1. Patient 1. (A) Scaly erythematous plaque on the left ear. (B) Typical malar rah. (C) Painful ulcer on the hard palate. Patient
2. (D) Edematous, erythematous plaque with scales on the left ear. (E) Facial malar rash, discoid rash with petechiae. (F) Periungual
erythema over the fingers.
mm/h). Forty-eight hours after admission, a follow-up 
blood test showed severe leukopenia (WBC count, 780/ 
mm
3) and anemia (hemoglobin, 7.8 g/dl) with reticul-
ocytosis.
Because more skin lesions appeared on the patient’s 
upper limbs, a skin biopsy was performed to exclude viral 
exanthema or other forms of inflammatory dermatosis. 
Five days following admission, a rheumatology test was 
positive for anti-nuclear antibody (ANA) with a speckled 
pattern (1:320), anti-dsDNA antibody (67.8 IU/ml; refe-
rence range, ＜10 IU/ml), and anticardiolipin immuno-
globulin M (IgM) (＞100 U/ml; reference range, ＜15 
U/ml). The complement 3 (C3) concentration was 22.5 
mg/dl (reference range, 90∼180 mg/dl), and the C4 
concentration was 6.2 mg/dl (10∼40 mg/dl). Histopa-
thology of the skin showed typical lupus dermatitis with 
characteristic thickening of the basement membrane and 
subtle interface changes, perivascular and periadnexal 
lymphocytic infiltration, and a positive lupus band (Fig. 
2A∼D). Based on the clinical, histopathological, and 
immunopathological findings, the final diagnosis was JSLE.
During hospitalization, the patient’s hemoglobin level 
declined progressively, but transfusion of packed red 
blood cells was prohibited because of positive results on 
direct and indirect Coombs tests. Based on the final 
diagnosis and deteriorating clinical course, induction im-
munosuppressive therapy with intravenous pulsed- steroid 
therapy (500 mg methylprednisolone/day) and oral medi-
cation (50 mg azathioprine/day) were prescribed. The 
patient became afebrile 3 days after treatment. Leukocyte 
and hemoglobin levels increased, and liver enzyme and 
bilirubin levels returned to normal. The cutaneous lesions 
resolved after 1 week. The medications were shifted to 
maintenance regimens with oral corticosteroid (30 mg/ 
day), azathioprine (50 mg/day), and mycophenolate mofe-
til (250 mg/day). The disease was controlled, the patient’s 
condition improved, and she was discharged from the 
hospital. At follow-up 10 months after discharge, the di-
sease was well controlled without cutaneous or systemic 
sequelae.
The second case was a 14-year-old girl who presented 
with a 1-month history of asymptomatic skin lesions on 
both ears. Three weeks later, she developed facial ery-
thema with edema and constitutional symptoms including 
fever, myalgia, and arthralgia. A physical examination at 
admission showed scaly erythematous plaques with ede-
ma on both ears (Fig. 1D). A facial malar rash and round 
well-demarcated plaques with petechiae on both cheeks 
were seen (Fig. 1E). She also had several erythematous pa-
pules on the back and cyanotic changes with periungual 
telangiectasia on all fingers and toes (Fig. 1F). Mucosal 
ulceration was observed on the hard palate.Scaly Ear Rash as a Herald of JSLE
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Fig. 2. Histological sections of skin biopsies, patient 1 (A) thickened basement membrane zone with dermal perivascular lymphocytic
infiltrate (B) subtle vacuolar degeneration and melanin incontinence (H&E, original magnification, A: ×20, B: ×40), immunofluorescence
staining revealing positive for lupus band (C) IgG and (D) IgM (original magnification, C: ×20, D: ×40). Patient 2 (E) positive lupus
band of IgM and (F) nuclear staining of IgG (original magnification, D: ×20, F: ×20).
Table 1. Association between cutaneous lupus erythematosus 
and systemic disease activity
5
Disease Systemic disease association 
  ACLE ++++
  LE-nonspecific disease ++++
  SCLE +++
  Generalized DLE ++
  Localized DLE +
  Hypertrophic LE +
  LE panniculitis +
  Tumid LE +
ACLE: acute cutaneous lupus erythematosus, LE: lupus ery-
thematosus, SCLE: subacute cutaneous lupus erythematosus, 
DLE: discoid lupus erythematosus. Correlation between cutaneous
lesion and systemic disease activity: + (rarely correlate), ++ 
(sometimes correlate), +++ (usually correlate), ++++ (always
correlate).
The laboratory examination showed pancytopenia: WBC 
count, 560/mm
3; hemoglobin, 8.1 g/dl; and platelet count, 
99×10
9/L (reference range, 150∼400×10
9/L). ANA with 
a speckled pattern (＞1:1,280) and a low C3 concen-
tration (44 mg/dl) were noted. Biochemical values were 
within the normal limits. A histopathological examination 
of the biopsy specimen taken from a papule on the back 
showed similar findings as those of  patient 1. An immu-
nofluorescence study showed granular deposition of IgG, 
IgM, IgA, and C3 at the epidermal-dermal junction as well 
as nuclear staining of IgG (Fig. 2E, F). The patient was 
diagnosed with JSLE, and she was treated with intravenous 
pulsed-steroid therapy (500 mg methylprednisolone/day). 
The fever subsided 2 days after treatment, and the skin 
lesions disappeared.
DISCUSSION
Hematological and cutaneous signs are the most common 
initial manifestation of JSLE
3. Compared with adult SLE, 
the initial presentation of JSLE is sometimes nonclassical 
and can be more severe
3. Diagnosis and treatment may be 
delayed in this age group. In 1981, Gilliam and Sonth-
eimer proposed that the cutaneous signs of lupus ery-
thematosus (LE) be divided into LE-specific and LE-non-
specific lesions
4. Acute cutaneous LE, subacute cutaneous 
LE, and chronic cutaneous LE are three specific lesions 
seen in SLE. In contrast, nonclassical presentations such as 
vasculitis, Raynaud’s phenomenon and periungual telan-CF Huang, et al
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Table 2. Differences between juvenile SLE and adult SLE
1
Clinical/laboratory 
manifestations Juvenile SLE Adult SLE
  Sicca symptoms + ++
  Fever ++ +
  Arthralgia + ++
  Anemia (hemolytic) ++ +
  Chilblains LE ++ +
  SCLE ++ +
  DLE + ++
  Kidney involvement ++ +
  Anti-dsDNA ++ +
  Anti-ribosomal P ++ +
  Antihistone ++ +
SLE: systemic lupus erythematosus, LE: lupus erythematosus,
SCLE: subacute cutaneous lupus erythematosus, DLE: discoid 
lupus erythematosus. One plus sign (+) indicates that a 
characteristic occurs frequently, 2 plus signs (+) indicate that 
a characteristic occurs more frequently.
giectasia are defined as LE-nonspecific lesions. Although 
not unique to LE, the nonspecific lesions are as important 
as the butterfly rash, whose appearance correlates strongly 
with disease activity (Table 1)
5. All of these lesions may 
occur in patients with SLE or in patients who do not fit the 
criteria for SLE
6. These different types of lesions may occur 
simultaneously in a patient with SLE
6.
Our patients might have ignored the erythematous and 
scaly changes on the ear because they may have consi-
dered them to be eczema or physiological flushing. How-
ever, we suspected that the persistent scaly erythema 
might reflect disease activity, because it was caused by 
inflammatory hyperemia
7. The scaly ear rashes were not 
sampled for histological examination, and we could not 
identify whether the rashes were LE specific or LE non-
specific. However, the ear rashes may provide an im-
portant dermatological clue for diagnosing JSLE early, 
regardless of which specialized group of cutaneous LE the 
ear lesion falls into. Hence, if a juvenile patient presents 
with a scaly ear rash followed by fever, leukopenia and 
anemia, we suggest that JSLE should be considered prom-
ptly.
The clinical and laboratory presentations of JSLE are 
similar to those of adult SLE
1, although the clinical mani-
festations and prevalence of autoantibodies vary between 
the two forms. Clinically, fever and organ involvement are 
significantly more frequent in JSLE, whereas arthralgia and 
sicca symptoms are more common in adult SLE
1. The most 
commonly affected organs are the brain and kidneys, 
particularly in black children
8. A laboratory examination 
will show that hemolytic anemia and antiribosomal P, 
anti-dsDNA, and antihistone antibodies are found more 
often in JSLE (Table 2)
1.
In contrast to adult SLE, children usually have a more 
severe clinical course, and large studies have revealed 
higher mortalities
9. In an international multicenter cohort 
study, the mortality rate was almost eight times greater for 
patients with SLE who were younger than 24 years of age 
compared with older patients
9. The complications of JSLE 
caused by infection or organ involvement including lupus 
nephritis determine the prognosis of JSLE. The therapeutic 
plan should focus on reducing morbidity and mortality 
rates. The overall treatment in juvenile patients is similar 
to that in adult patients and depends on the clinical 
manifestations and the major organs involved. There are 
two parts to modern therapeutic strategies of JSLE
10. The 
first part is induction therapy to control disease activity; 
potential organ-threatening or life-threatening disease 
must be managed aggressively. After remission, the se-
cond part is maintenance therapy to avoid relapse and to 
control the disease, and most patients need to be treated 
for several years
10. Immunosuppressants are the drugs of 
choice in both parts of treatment, although efficacy and 
side effects must be balanced.
We believe that scaly ear rash seems be overlooked in the 
literature, because it can be an underestimated and easily 
ignored skin lesion in children with SLE. This lesion could 
be an initial sign preceding other systemic symptoms. 
Hence, when patients present with this type of skin lesion, 
they should be followed up regularly to provide early 
diagnosis and management.
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